SCHEMBL683446

SCHEMBL683446

COC(=O)[C@@H]1CCCN1C(=O)[C@H](C)CSSC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PEPD P12955 3/20 0.51
ACE P12821 7/20 0.50
REN P00797 4/20 0.50
KDM4E B2RXH2 1/20 0.50
F2 P00734 1/20 0.50
LMNA P02545 1/20 0.50
LTA4H P09960 1/20 0.50
MAPT P10636 1/20 0.50
ALOX15 P16050 1/20 0.50
PTGS1 P23219 1/20 0.50
HTR2A P28223 1/20 0.50
PTGS2 P35354 1/20 0.50
HRH1 P35367 1/20 0.50
THPO P40225 1/20 0.50
PMP22 Q01453 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ACE2 Q9BYF1 1/20 0.50
XPNPEP1 Q9NQW7 1/20 0.48
POLB P06746 1/20 0.47
FKBP1A P62942 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11548029 0.95 PEPD (0.47) PEPDACERENKDM4EF2
SCHEMBL7377578 0.88 PEPD (0.48) PEPDACERENKDM4EF2
SCHEMBL682290 0.86 FKBP1A (0.48) PEPDACERENKDM4EF2
SCHEMBL18124445 0.85 PEPD (0.53) PEPDACERENKDM4EF2
SCHEMBL27015252 0.85 PEPD (0.53) PEPDACERENKDM4EF2
SCHEMBL18595211 0.85 PEPD (0.53) PEPDACERENKDM4EF2
SCHEMBL19908871 0.84 PEPD (0.52) PEPDACERENKDM4EF2
SCHEMBL683116 0.84 ACE (0.71) PEPDACERENKDM4EF2
SCHEMBL21533006 0.84 ACE (0.71) PEPDACERENKDM4EF2
SCHEMBL12191496 0.84 PEPD (0.52) PEPDACERENKDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS BRAINCELLS INC. (US) 2011-02-24 US disclosed
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS BRAINCELLS INC. (US) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046090-A1 MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS GAP43, GABRB1, GABRB3 PEPD 4236/4885ACE 4514/4885REN 4301/4885
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF PEPD 366/4885ACE 6/4885REN 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.